Tackling obesity and co-morbidities: a metabolic revolution is underway
April 8th 2025
Anti-obesity drugs are no longer just about shedding pounds, they’re becoming central to addressing broader metabolic health challenges.
The round table discussion explored the transformative potential of GLP-1 agonists like Novo Nordisk’s Wegovy® and Lilly’s alternatives, both of which are generating over $1 billion in quarterly sales.
But the conversation quickly evolved beyond weight loss. Experts highlighted the ripple effect these drugs could have on reducing cardiovascular disease, diabetes, osteoarthritis, and even Alzheimer’s, conditions often tied to obesity as a root cause. This makes them powerful tools not just for individual patients but for entire healthcare systems, potentially saving millions in long-term costs.
The panel also discussed the role of digital innovation, particularly AI, in enhancing treatment outcomes through population surveillance and real-time monitoring. As one panellist noted, this shift aligns with a broader industry trend: moving from simply extending life to enhancing the quality of life.
“This shift aligns with a broader industry trend: moving from simply extending life to enhancing the quality of life.”
The global market for these treatments is forecast to exceed $100 billion by 2030. With such massive potential, both clinically and commercially, metabolic health innovation is a space to watch closely.
Are you seeking a trusted partner to support your executive search in Life Sciences?
We bring decades of executive search experience and a proven track record of success across our dedicated sectors. Our investor clients rely on us time and again to build exceptional leadership teams that drive growth and deliver results.
